Toggle Main Menu Toggle Search

Open Access padlockePrints

Impact of genomic risk factors on outcome after hematopoietic stem cell transplantation for patients with chronic myeloid leukemia

Lookup NU author(s): Professor Anne Dickinson, Dr Kim Pearce, Jean Norden


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Background: Non-HLA gene polymorphisms have been shown to influence outcome after allogeneic hematopoietic stem cell transplantation. Results were derived from heterogeneous, small populations and their value remains a matter of debate.Design and Methods: In this study, we assessed the effect of single nucleotide polymorphisms in genes for interleukin 1 receptor antagonist (IL1RN), interleukin 4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10), interferon (IFNG), tumor necrosis factor (TNF) and the cell surface receptors tumor necrosis factor receptor II (TNFRSFIB), vitamin D receptor (VDR) and estrogen receptor alpha (ESR1) in a homogeneous cohort of 228 HLA identical sibling transplants for chronic myeloid leukemia. Three good predictors of overall survival, identified via statistical methods including Cox regression analysis, were investigated for their effects on transplant-related mortality and relapse. Predictive power was assessed after integration into the established European Group for Blood and Marrow Transplantation (EBMT) risk score.Results: Absence of patient TNFRSFIB 196R, absence of donor IL10 ATA/ACC and presence of donor IL1RN allele 2 genotypes were associated with increased transplantation-related mortality and decreased survival. Application of prediction error and concordance index statistics gave evidence that integration improved the EBMT risk score.Conclusions: Non-HLA genotypes were associated with survival after allogeneic hematopoietic stem cell transplantation. When three genetic polymorphisms were added into the EBMT risk model they improved the goodness of fit. Non-HLA genotyping could, therefore, be used to improve donor selection algorithms and risk assessment prior to allogeneic hematopoietic stem cell transplantation.

Publication metadata

Author(s): Dickinson AM, Pearce KF, Norden J, O'Brien S, Holler E, Bickeboller H, Balavarca Y, Vanderson R, Kolb HJ, Hromadnikova I, Sedlacek P, Niederwieser D, Brand R, Ruutu T, Apperley J, Szydlo R, Goulmy E, Siegert W, de Witte T, Gratwohl A

Publication type: Article

Publication status: Published

Journal: Haematologica

Year: 2010

Volume: 95

Issue: 6

Pages: 922-927

Print publication date: 19/03/2010

ISSN (print): 0390-6078

ISSN (electronic): 1592-8721

Publisher: Fondazione Ferrata Storti


DOI: 10.3324/haematol.2009.016220


Altmetrics provided by Altmetric


Funder referenceFunder name
Celegene International SARL
Chugai Sanofi Aventis SNC
F Hoffmann-La Roche
Gambro BCT
GE Healthcare
Horton Foundation.
Laboratoires Pierre Fabre
Miltenyi Biotec GmbH
Regional Cancer League
Amgen Europe GmbH
Berlex AG (Schering AG Germany)
Bristol Myers Squibb
Fresenius Biotech GmbH
Gilead Sciences
Schering-Plough International Inc.
Swiss Cancer League
3200B0-118176Swiss National Research Foundation
LSH-2002-2.2.0-3European Leukemia Net
QLRI-CT-200000010European Commission